Melanoma Risk From Biologic Therapy Remains Uncertain
Clinically important increases in melanoma risk in patients treated with biologic therapy for common inflammatory diseases cannot be ruled out based on current evidence.
Melanoma
Mole Patrol: A Case of Disseminated Melanoma
The clinical presentation of melanoma varies between patients, stage of diagnosis, subtype, and may initially present the same as any other pigmented macule or patch on the skin.
Exposure to Antibiotics Associated With Survival Detriment in Patients With Advanced Melanoma Treated With ICIs
Previous studies have shown an association between gut microbiome diversity and response to immune checkpoint inhibitor therapy.
FDG-PET Superior to CT for Predicting Melanoma Relapse After Immunotherapy
The long-term outcome of patients with melanoma may be predicted by FDG-PET imaging and also influence treatment duration.
PET, CT Scans for the Staging of Malignant Melanoma
Findings suggest that PET/CT imaging should be included in the malignant melanoma treatment algorithm starting with T2 patients.
Malignant Cutaneous Tumors of the Scalp: Difficult to Identify, Manage
A number of factors underscore the importance of careful examination of the scalp for skin cancers during consultation.
Continuous Dosing of BRAF/MEK Inhibition Superior to Intermittent Dosing in Melanoma
Continuous dosing of dabrafenib-trametinib resulted in prolonged PFS compared with intermittent dosing in advanced BRAF-mutated advanced melanoma.
Atezolizumab Plus BRAF/MEK Inhibition Prolonged PFS in Melanoma
Atezolizumab plus cobimetinib and vemurafenib prolonged PFS in unresectable or metastatic melanoma compared with placebo and BRAF/MEK inhibition in the phase 3 IMspire150 trial.
New Dosing Schedule Approved for All Keytruda Indications
The FDA has approved the supplemental Biologics License Application (sBLA) for Keytruda® (Merck) to include an additional recommended dosage of 400mg every 6 weeks across all adult indications.
Model Could Help Identify Who May Respond to Checkpoint Inhibition in Melanoma
Imaging radiomics and blood markers could differentiate pseudoprogression.
-
Loading...
-
Loading...
Next post in Skin Cancer
